Dermatology and Therapy最新文献

{"title":"Platelet-Rich Plasma in the Management of Alopecia: A Systematic Review and Meta-Analysis of Clinical Evidence.","authors":"Eduardo Anitua, Roberto Tierno, Mohammad Hamdan Alkhraisat","doi":"10.1007/s13555-025-01542-8","DOIUrl":"https://doi.org/10.1007/s13555-025-01542-8","url":null,"abstract":"<p><strong>Introduction: </strong>Alopecia is a common hair loss condition with different treatment modalities. Platelet-rich plasma (PRP), a minimally invasive autologous therapy, has emerged as a topic of interest, but its effectiveness remains debated. The present systematic review and meta-analysis aims to evaluate the safety and efficacy of PRP for alopecia.</p><p><strong>Methods: </strong>A comprehensive search of PubMed, EMBASE, and Scopus conducted on 27 May 2025 with monthly updates until July 10 2025 identified 43 randomized controlled trials (1877 participants) assessing PRP in alopecia. Primary outcomes were changes in hair density and thickness. Secondary outcomes included side effects, hair loss, clinical improvement, patient satisfaction, recurrence, and other hair follicle metrics.</p><p><strong>Results: </strong>Activated PRP was effective in increasing hair density and minimizing recurrence compared with placebo, whereas non-activated PRP was associated with a higher frequency of adverse effects. PRP also improved clinical outcomes and patient satisfaction. Moreover, hair loss decreased with PRP therapy regardless of activation status or control type. However, PRP did not significantly affect hair thickness. However, PRP did not significantly affect hair thickness.</p><p><strong>Discussion: </strong>These findings support PRP as a relatively safe and effective therapy for alopecia, particularly in increasing hair density and reducing hair loss. Patient satisfaction was generally favorable. The clinical efficacy of PRP was often comparable or superior to conventional treatments. Activation status appears to influence response, highlighting the importance of preparation protocols. However, as a result of heterogeneity in study designs and incomplete reporting of the effect of specific PRP composition-related covariates on treatment efficacy or patient safety outcomes, no significant variation in overall effect modification was attributable to alopecia subtype.</p><p><strong>Conclusions: </strong>Moderate evidence highlights that PRP is safe and effective in improving hair density, reducing hair loss, and enhancing clinical outcomes and satisfaction. No significant benefits were demonstrated for hair thickness or other follicle-related parameters as derived from PRP therapy. Further high-quality, standardized trials are needed to confirm these findings and clarify the clinical significance of PRP formulations.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145052242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons.","authors":"Stephano Cedirian, Monia Donati, Luca Rapparini, Francesca Pampaloni, Michelangelo La Placa, Rossella Sgarzani, Luca Negosanti, Emanuel Raschi, Michela Starace","doi":"10.1007/s13555-025-01537-5","DOIUrl":"https://doi.org/10.1007/s13555-025-01537-5","url":null,"abstract":"<p><p>Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have gained prominence for their efficacy in treating type 2 diabetes and obesity. Recent evidence suggests that their pleiotropic effects-beyond glycemic control and weight loss-include anti-inflammatory, immunomodulatory, and antioxidative effects, which may beneficially support various dermatologic conditions such as psoriasis, hidradenitis suppurativa, acanthosis nigricans, and Hailey-Hailey disease. However, GLP-1 RAs are also associated with emerging cutaneous adverse drug reactions, including bullous, exanthematous and vasculitic manifestations, and other rare side effects. In aesthetic and reconstructive surgery, rapid weight loss induced by these agents has raised concerns regarding facial volume depletion, skin laxity, and impaired wound healing. In addition, perioperative management of patients on GLP-1 RAs requires careful assessment as a result of delayed gastric emptying and the associated potential risk of pulmonary aspiration. This narrative review summarizes current knowledge on the benefit/risk profile of GLP-1 RAs, highlighting their impact for dermatologists and plastic surgeons in relevant contexts.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145023109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rocatinlimab: A Novel T-Cell Rebalancing Therapy Targeting the OX40 Receptor in Atopic Dermatitis.","authors":"Emma Guttman-Yassky, Eric Simpson, Ehsanollah Esfandiari, Hirotaka Mano, Jillian Bauer, Prista Charuworn, Kenji Kabashima","doi":"10.1007/s13555-025-01492-1","DOIUrl":"https://doi.org/10.1007/s13555-025-01492-1","url":null,"abstract":"<p><p>Atopic dermatitis (AD) is a chronic inflammatory disease characterized by eczematous skin lesions, intense pruritus, skin pain, sleep disruption, and mental health disturbances. There remains a need for a therapeutic option that delivers durable efficacy, safety, and convenient dosing across the AD patient population. This review provides an overview of AD pathogenesis driven by T-cell imbalance and describes a novel therapeutic option targeting the OX40 receptor, a costimulatory molecule expressed specifically on activated T cells. Expression of the OX40 receptor on skin-homing T cells is increased in AD. OX40-mediated activation of pathogenic T cells drives inflammation in AD and is critical for the formation of memory T cells, leading to persistent disease. Rocatinlimab (AMG 451/KHK4083) is a novel T-cell rebalancing therapy that inhibits and reduces pathogenic T cells by targeting the OX40 receptor. By reducing pathogenic T-cell number and activity, rocatinlimab has the potential to limit AD flares and modify the course of disease. Rocatinlimab showed promise for the treatment of moderate-to-severe AD in a phase 2b trial, significantly improving overall disease severity, skin involvement, pruritus, sleep disturbance, and quality of life compared with placebo at week 16. Improvements continued through week 36 during active treatment, and notably, were largely maintained in responders throughout a subsequent 20-week off-treatment period, providing evidence for durable on and off treatment responses. Rocatinlimab has also demonstrated a favorable safety and tolerability profile. A large, global phase 3 program (ROCKET) including eight studies is underway to further assess the efficacy, safety, maintenance of response, extended dosing, and off-treatment durability of rocatinlimab in adults and adolescents with moderate-to-severe AD.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145005961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Zabedosertib, an Interleukin-1 Receptor-Associated Kinase 4 Inhibitor, in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase II Randomized Study.","authors":"Stefan J Jodl, Margitta Worm, Frauke Friedrichs, Ulrike Heinzel-Pleines, Andrea Wagenfeld, Maximilian Feldmüller, Stefan Klein, Ruiping Zhang, Kaweh Shakery, Ruth D Holzmann, Beate Rohde, Vidya Perera","doi":"10.1007/s13555-025-01505-z","DOIUrl":"https://doi.org/10.1007/s13555-025-01505-z","url":null,"abstract":"<p><strong>Introduction: </strong>Interleukin-1 receptor-associated kinase 4 (IRAK4) is expressed in various immune cells and regulates proinflammatory cytokine production. Its inhibition represents a novel, promising therapeutic option in the treatment of atopic dermatitis (AD). Zabedosertib (BAY1834845) is a potent, selective IRAK4 inhibitor that suppresses markers of local and systemic immune responses. This study aimed to evaluate the efficacy and safety of zabedosertib in adults with moderate-to-severe AD.</p><p><strong>Methods: </strong>DAMASK was a randomized, double-blind, 12-week, placebo-controlled, phase 2a, proof-of-concept study. Patients were randomized 2:1 to receive oral zabedosertib 120 mg twice daily or placebo. The primary efficacy endpoint was a composite of 75% reduction from baseline on the Eczema Area and Severity Index (EASI-75), no discontinuation of study medication for lack of efficacy, no rescue medication during the 4 weeks before Day 84, and no initiation of systemic AD treatment. Other efficacy assessments included validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD), Peak Pruritus numerical rating scale score, and affected body surface area (BSA); for safety, it included frequency and severity of treatment-emergent adverse events (TEAEs).</p><p><strong>Results: </strong>Of 77 randomized patients, 69 were included in the primary efficacy analysis (zabedosertib, n = 47; placebo, n = 22); 55 patients completed treatment. At Week 12, there was no significant difference between zabedosertib and placebo in the primary efficacy endpoint (32.3% vs. 37.4%) or percentage change in EASI from baseline (- 44.6% vs. - 55.9%). There were also no significant differences between zabedosertib and placebo at Week 12 in vIGA-AD response (15.9% vs. 28.5%), Peak Pruritus response (16.4% vs. 25.0%), percentage change in Peak Pruritus (- 20.7% vs. - 27.3%), or percentage change in BSA affected by AD (- 13.3% vs. - 20.3%). No severe or serious TEAEs were reported throughout the study.</p><p><strong>Conclusions: </strong>Zabedosertib was safe and well tolerated in adults with moderate-to-severe AD but showed no evidence of efficacy in reducing disease severity or pruritus in this placebo-controlled study.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier, NCT05656911.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Network Meta-analysis of 1.5% Ruxolitinib Cream Versus Systemic Agents in the Treatment of Moderate Atopic Dermatitis.","authors":"Melinda J Gooderham, H Chih-Ho Hong, Di Wang, Becky Hooper, Avery Hughes-Martin, Heather Cameron, Laura Pastor, Alicia Pepper, Ping Wu, Ali Mojebi, Grace Wong, Rafael Marino, Marie-Lise Dion, Mehdi Larbi","doi":"10.1007/s13555-025-01503-1","DOIUrl":"https://doi.org/10.1007/s13555-025-01503-1","url":null,"abstract":"<p><strong>Introduction: </strong>Atopic dermatitis (AD) is a chronic, highly pruritic, relapsing inflammatory disease associated with high quality-of-life burden. Topical 1.5% ruxolitinib cream is a selective Janus kinase (JAK)1/JAK2 inhibitor that is well tolerated and effective in improving itch and lesion clearance in patients ≥ 12 years old. This analysis estimates comparative efficacy for 1.5% ruxolitinib cream relative to systemic therapies for treatment of patients ≥ 12 years with AD.</p><p><strong>Methods: </strong>A systematic literature review (SLR) identified randomized controlled trials evaluating 1.5% ruxolitinib cream, oral JAK inhibitors, monoclonal antibodies, phosphodiesterase 4 inhibitors, and systemic immunosuppressants. A feasibility assessment evaluated whether indirect treatment comparison (ITC) was appropriate and determined appropriate ITC methods. This network meta-analysis (NMA) assessed the comparative efficacy of 1.5% ruxolitinib cream against systemic therapies in a \"systemic-eligible moderate AD\" subgroup defined as ≥ 12 years old and eligible for topical and systemic therapies (Investigator's Global Assessment [IGA] = 3, Eczema Area and Severity Index [EASI] ≥ 16, and body surface area ≥ 10%); an ITC with the full study populations was not feasible. A frequentist framework using a penalized likelihood NMA included outcomes of IGA 0/1 with at least a 2-point improvement from baseline, EASI-75, and Itch Numerical Rating Scale 4 (NRS4).</p><p><strong>Results: </strong>The SLR identified 25 studies, of which 12 reported outcomes for the relevant subgroup for four interventions: 1.5% ruxolitinib cream, dupilumab 300 mg, upadacitinib (15 mg, 30 mg), and abrocitinib (100 mg, 200 mg), which were compared against placebo or placebo + topical corticosteroids. There were no statistically significant differences between active comparators for IGA 0/1, EASI-75, and Itch NRS4, although point estimates numerically favored 1.5% ruxolitinib cream for IGA 0/1 and EASI‑75.</p><p><strong>Conclusion: </strong>For patients with moderate AD who are eligible for systemic therapies, 1.5% ruxolitinib cream might provide disease control comparable to systemic treatments, such as dupilumab, regarding IGA 0/1, EASI-75, and Itch NRS4.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Strategies for Optimal Use of Biological Therapies in Managing Psoriasis: Focus on Secukinumab.","authors":"Anna Balato, Martina Burlando, Anna Campanati, Antonio Costanzo, Andrea Chiricozzi, Paolo Gisondi, Piergiorgio Malagoli, Giuseppe Micali","doi":"10.1007/s13555-025-01515-x","DOIUrl":"https://doi.org/10.1007/s13555-025-01515-x","url":null,"abstract":"<p><strong>Introduction: </strong>Psoriasis (PsO) is a common inflammatory dermatological condition with a substantial negative impact on patient quality of life. Several biological agents are available for the treatment of PsO, and clinicians and patients must consider various factors when deciding on the most appropriate biological agent.</p><p><strong>Methods: </strong>Here, we report a set of consensus statements developed by an Italian PsO advisory board on use of the anti-interleukin-17A biological secukinumab in routine clinical practice.</p><p><strong>Results: </strong>The statements were developed under three main topics, the first of which was \"characteristics of secukinumab and criteria for patient selection to achieve long-term benefits\". This statement helps to identify patients most likely to benefit from secukinumab, including biological-naïve patients with moderate PsO; patients with PsO involving sensitive sites; patients in whom biosimilar anti-tumour necrosis factor-alpha treatment has proved ineffective; patients at high risk of developing psoriatic arthritis; lean or normal-weight patients; patients with active disease receiving conventional disease-modifying antirheumatic drugs; and patients with comorbidities, including cardiovascular disease. Under the second topic, \"strategies to maintain secukinumab effectiveness in the long term\", the advisors highlighted the importance of patient support to promote adherence; weight control; understanding that PsO can worsen for reasons unrelated to treatment; and understanding that appropriate treatment should depend on the severity of any disease worsening. The third topic, \"strategies for patient support to promote adherence to therapy\", noted the importance of patient education, accurate disease assessments and treatment tailoring.</p><p><strong>Conclusion: </strong>These consensus statements will help guide dermatologists in the selection of patients with PsO for whom secukinumab is the most appropriate treatment in real-world clinical practice in Italy.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Skin Patting and Iontophoresis with Dutasteride Gel in Male and Menopausal Female Androgenetic Alopecia: A Pilot Study.","authors":"Stephano Cedirian, Francesca Pampaloni, Federico Quadrelli, Luca Rapparini, Francesca Bruni, Ginevra Martelli, Bianca Maria Piraccini, Michela Starace","doi":"10.1007/s13555-025-01532-w","DOIUrl":"https://doi.org/10.1007/s13555-025-01532-w","url":null,"abstract":"<p><strong>Introduction: </strong>Androgenetic alopecia (AGA) is a chronic, progressive condition often resistant to conventional treatments. Transdermal delivery systems such as iontophoresis and skin patting (SPi) may enhance drug penetration and follicular targeting. Dutasteride, a potent dual 5α-reductase inhibitor, has shown superior efficacy to finasteride, but topical delivery is limited by variable absorption. In this pilot study, we evaluated the efficacy and safety of dutasteride gel delivered via SPi and iontophoresis in men and postmenopausal women with treatment-resistant AGA.</p><p><strong>Methods: </strong>In this single-center pilot study, 20 adults (10 males, 10 postmenopausal females) with AGA unresponsive to ≥ 12 months of standard therapy underwent four monthly sessions of SPi and iontophoresis with 6% dutasteride gel. Hair density, shaft diameter, and pull test results were assessed at baseline and 8 weeks post-treatment; patient satisfaction (0-4 scale) and safety were recorded. Paired tests were used to analyze the results, with p < 0.05 considered to indicate significance.</p><p><strong>Results: </strong>Hair density improved significantly in frontal (p < 0.001) and vertex (p < 0.001) regions. Shaft diameter increased in vertex (p < 0.001) and frontal areas (p = 0.046). Pull test scores improved (p < 0.001). Mean satisfaction was 3.4/4. No adverse events occurred.</p><p><strong>Conclusion: </strong>SPi with iontophoresis effectively delivered topical dutasteride, yielding significant clinical improvement and excellent safety in treatment-resistant AGA. Larger randomized trials are warranted to confirm these findings.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144946286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Translational Pharmacokinetics of Icotrokinra, a Targeted Oral Peptide that Selectively Blocks Interleukin-23 Receptor and Inhibits Signaling.","authors":"Beverly Knight, Brinda Tammara, Nishit B Modi, Shannon Dallas, Saro Mardirosian, Jianyao Wang, Aline Laenen, Laurent Leclercq, Karen DiLoreto, Lieve Adriaenssen, Darren Moss, David Polidori, Siladitya Ray Chaudhuri, Seonghee Park, Carlo Sensenhauser, Anthony Ndifor, Siddharth Sukumaran, Tristan Baguet, Yifan Shi, Shefali Patel, Brian Geist, Anne Fourie, Raymond Patch, Chengzao Sun, Stephanie A Barros, Sandeep Somani, Mario Monshouwer","doi":"10.1007/s13555-025-01454-7","DOIUrl":"10.1007/s13555-025-01454-7","url":null,"abstract":"<p><strong>Introduction: </strong>Icotrokinra (formerly JNJ-77242113 or PN-21235) is a targeted oral peptide that selectively inhibits interleukin-23 receptor signaling. The studies described here assessed its absorption, distribution, metabolism, and excretion (ADME), and potential for drug-drug interactions (DDI).</p><p><strong>Methods: </strong>In vitro assays evaluated permeability, plasma protein binding, blood-to-plasma partitioning, metabolic stability, and interactions with drug transporters and metabolic enzymes. The nonclinical pharmacokinetic properties of icotrokinra were studied in vivo in rats and monkeys. Phase 1 studies evaluated the pharmacokinetic profile, metabolic profile and excretion in healthy volunteers.</p><p><strong>Results: </strong>Icotrokinra demonstrated oral bioavailability of 0.1-0.3% in animals, with evidence of systemic pharmacodynamic activity, without the use of an absorption enhancer. The compound was stable across species in plasma, gastrointestinal matrices, and hepatocytes. Protein binding was low across species (~ 50% in human plasma), and icotrokinra distributed freely to tissues, including skin, joints, and gastrointestinal tissues. Following oral dosing in both rats and monkeys, fecal excretion of unabsorbed drug was the primary elimination route, and metabolite levels were low (each < 2% of dose) in plasma and excreta, with unchanged icotrokinra being the main circulating component. Icotrokinra was neither a substrate nor an inhibitor of prototypical drug transporters or cytochrome P450 enzymes. Icotrokinra exhibited dose-proportional pharmacokinetics from 25 mg to 1000 mg in a first-in-human study, and no serious adverse events were identified following single and multiple dose administrations. Unchanged icotrokinra was the only drug-related component in human plasma.</p><p><strong>Conclusions: </strong>Icotrokinra exhibited high stability and an ADME profile consistent with that of a small peptide, with no risk of DDI identified on the basis of in vitro studies. Clinical data demonstrated linear pharmacokinetics and no major metabolites.</p><p><strong>Trial registration number: </strong>ClinicalTrials.gov, NCT04621630. Euclinicaltrials.eu, EUCT: 2023-504720-26-00. A Graphical Abstract is available for this article.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2495-2520"},"PeriodicalIF":4.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12354395/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144590671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Factors Associated with Clinical Improvement Following Energy-Based Device Treatment in Thai Patients with Atrophic Acne Scars: A Retrospective Study.","authors":"Chadakan Yan, Phichayut Phinyo, Yuri Yogya, Mati Chuamanochan, Rungsima Wanitphakdeedecha","doi":"10.1007/s13555-025-01486-z","DOIUrl":"10.1007/s13555-025-01486-z","url":null,"abstract":"<p><strong>Introduction: </strong>Acne scarring is a prevalent complication of acne vulgaris, often resulting in significant psychosocial distress. While energy-based devices (EBDs), including fractional laser (FL) and fractional radiofrequency (FRF), are increasingly used for atrophic acne scars, limited data exist on prognostic factors predicting treatment outcomes, particularly in Asian populations. The study aims to identify clinical predictors of graded clinical improvement in patients with atrophic acne scars treated with FL and FRF.</p><p><strong>Methods: </strong>This retrospective cohort study was conducted at a university hospital in Bangkok, Thailand, from 2012 to 2023. Clinical improvement was assessed using standardized photographic evaluations and categorized into four levels: < 25%, 25-50%, 51-75%, and > 75% improvement. Univariable and multivariable ordinal logistic regression models were used to determine prognostic factors. Sensitivity analyses were performed to confirm the robustness of the findings.</p><p><strong>Results: </strong>A total of 397 patients were included, of whom 254 received FL and 143 received FRF treatments. Older age (per 5-year increase) (mOR: 1.24; 95% CI: 1.07-1.43), male sex (mOR: 1.29; 95% CI: 1.06-1.57), shorter scar duration (per 5 years) (mOR: 0.73; 95% CI: 0.56-0.97), lower Fitzpatrick skin phototypes, and completion of at least three treatment sessions (mOR: 1.33; 95% CI: 1.16-1.53) were independently associated with greater clinical improvement. Sensitivity analyses confirmed the robustness of these associations.</p><p><strong>Conclusions: </strong>Key clinical factors, including patient age, sex, scar duration, skin phototype, and completion of at least three treatment sessions, significantly influence treatment outcomes with EBDs. These findings support the development of personalized treatment strategies to optimize outcomes, particularly in patients with severe scarring.</p><p><strong>The trial registration number: </strong>TCTR20240512006.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2571-2581"},"PeriodicalIF":4.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12354357/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144616667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bimekizumab Impact on Patient-Reported Outcomes in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II.","authors":"Vivian Y Shi, John R Ingram, Hadar Lev-Tov, Sylke Schneider-Burrus, Seth Forman, Martina L Porter, Koremasa Hayama, Linnea Thorlacius, Jérémy Lambert, Tom Vaux, Bartosz Lukowski, Robert L Rolleri, Jacek C Szepietowski","doi":"10.1007/s13555-025-01465-4","DOIUrl":"10.1007/s13555-025-01465-4","url":null,"abstract":"<p><strong>Introduction: </strong>Hidradenitis suppurativa (HS) symptoms (pain, itch, odour and drainage) impair quality of life (QoL). Bimekizumab, a humanised IgG1 monoclonal antibody, selectively inhibits interleukin (IL)-17A and IL-17F. The impact of bimekizumab on patient-reported outcomes (PROs) was assessed using pooled 48-week data from BE HEARD I&II (BHI&II) studies in moderate to severe HS.</p><p><strong>Methods: </strong>Patients received (initial/maintenance) bimekizumab 320 mg every 2 weeks (Q2W)/Q2W, bimekizumab Q2W/Q4W, bimekizumab Q4W/Q4W or placebo/bimekizumab Q2W. HS Symptom Daily Diary (HSSDD) and HS Symptom Questionnaire (HSSQ) captured HS-specific patient-reported symptoms; HS Quality of Life questionnaire (HiSQOL^©) and Dermatology Life Quality Index (DLQI) captured health-related QoL (HRQoL). Change from baseline (CfB) and proportions of patients achieving clinically meaningful improvement thresholds or low disease impact are reported to Week 48 (observed case).</p><p><strong>Results: </strong>Of 1014 randomised patients, 868 received bimekizumab and 146 placebo. Greater numerical reductions at Week 16 were observed across HSSDD/HSSQ scores with bimekizumab vs placebo. From Week 16 to 48, HSSQ scores further numerically reduced with continuous bimekizumab and substantially reduced for placebo/bimekizumab switchers. At Week 16, bimekizumab showed numerically greater improvement in HRQoL vs placebo (HiSQOL total score mean CfB: - 11.7 to - 10.3 vs - 5.5). HiSQOL response rate (21-point total score reduction) was numerically higher by Week 4 in bimekizumab-treated patients (17.2-21.4%) vs placebo (9.2%); rates increased to Week 48 with continuous bimekizumab (42.0-47.4%) and in switchers (55.0%). Patients with very severe disease impact (HiSQOL total score ≥ 24) decreased over time with bimekizumab. At Week 16, DLQI minimal clinically important difference (4-point decrease) achievement was numerically greater with bimekizumab vs placebo (54.9-64.6% vs 49.1%). Achievement increased to Week 48 and switchers attained similar proportions (63.5-74.5% vs 76.5%). Comparable trends were observed for DLQI score of 0/1 (no HRQoL impact) achievement rates.</p><p><strong>Conclusion: </strong>Bimekizumab demonstrated clinically meaningful improvements by Week 4 in HRQoL, which were maintained over 1 year across PROs in patients with moderate to severe HS. Graphical Abstract available for this article.</p><p><strong>Trial registration: </strong>NCT04242446; NCT04242498.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2553-2570"},"PeriodicalIF":4.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12354430/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144616665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}